Latest Articles

Publication Date
Guttate Psoriasis Triggered by Streptococcal Pharyngitis in Older Patients: A Case Report.

BACKGROUND Guttate psoriasis is a form of psoriasis that often occurs following infections and is most commonly triggered by group A Streptococcus. The link between streptococcal pharyngitis and the development …

Published: Feb. 19, 2026, midnight
TMEM119 Links to Ovarian Endometriosis Progression via MAPK-Mediated Suppression of Ectopic Endometrial Stromal Cell Senescence.

Transmembrane protein TMEM119 has been implicated in tumor progression (e.g., ovarian cancer), but its role and underlying mechanism in ovarian endometriosis (EM) remain elusive. Thus, this study aimed to investigate …

Published: Feb. 19, 2026, midnight
Brenner tumor associated with mucinous cyst and endometriosis: a case report.

Brenner tumors are rare ovarian neoplasms that often coexist with other epithelial tumors, most commonly mucinous cystic neoplasms. The association of Brenner tumors with endometriosis is unusual and not well-documented …

Published: Feb. 19, 2026, midnight
Aprea reports second partial response in endometrial cancer trial - Investing.com Nigeria

Aprea reports second partial response in endometrial cancer trial Investing.com Nigeria

Published: Feb. 18, 2026, 11:46 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Aprea reports second partial response in endometrial cancer trial - Investing.com

Aprea reports second partial response in endometrial cancer trial Investing.com

Published: Feb. 18, 2026, 1:42 p.m.
GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk - European Medical Journal

GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk European Medical Journal

Published: Feb. 18, 2026, noon
GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk - EMJ | Elevating the quality of healthcare globally

GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk EMJ | Elevating the quality of healthcare globally

Published: Feb. 18, 2026, noon
This surgery could slash the risk of the deadliest female cancer by almost 80% - SMH.com.au

This surgery could slash the risk of the deadliest female cancer by almost 80% SMH.com.au

Published: Feb. 18, 2026, 8 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!